Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
J Am Coll Cardiol. 2011 Nov 15;58(21):2218-24. doi: 10.1016/j.jacc.2011.07.041.
The goal of this study was to determine the long-term clinical efficacy of percutaneous repair of paravalvular prosthetic regurgitation.
Percutaneous repair has emerged as an effective therapy for patients with paravalvular prosthetic regurgitation.
We retrospectively identified 126 patients who underwent catheter-based treatment of symptomatic prosthetic paravalvular regurgitation. Patients were contacted for symptoms, clinical events, and vital status.
The 3-year estimate for survival was 64.3% (95% confidence interval: 52.1% to 76.8%). Mortality occurred due to cardiac, noncardiac, and unknown causes in 9.5%, 7.1%, and 5.6% of patients, respectively. Among survivors, 72% of patients who had presented with heart failure were free of severe symptoms and need for cardiac surgery. Severity of residual regurgitation was not related to overall survival but was an important determinant of other clinical events. For those with no, mild, or moderate or severe residual regurgitation, 3-year estimate of survival free of death or need for surgery was 63.3%, 58.3%, and 30.3% (p = 0.01), respectively.
Percutaneous repair of paravalvular prosthetic regurgitation can lead to durable symptom relief in selected patients. Nonetheless, mortality remains significant in symptomatic patients with paravalvular prosthetic regurgitation. Long-term clinical efficacy is highly dependent on residual regurgitation.
本研究旨在确定经皮修复瓣周漏的长期临床疗效。
经皮修复已成为瓣周漏患者的有效治疗方法。
我们回顾性地确定了 126 例接受导管治疗症状性瓣周漏的患者。联系患者了解症状、临床事件和生存状况。
3 年生存率估计为 64.3%(95%置信区间:52.1%至 76.8%)。9.5%、7.1%和 5.6%的患者分别因心脏、非心脏和未知原因死亡。在幸存者中,72%的心力衰竭患者无严重症状且无需心脏手术。残余反流的严重程度与总生存率无关,但却是其他临床事件的重要决定因素。对于无、轻度、中度或重度残余反流的患者,3 年无死亡或手术生存率分别为 63.3%、58.3%和 30.3%(p = 0.01)。
经皮修复瓣周漏可在选择的患者中获得持久的症状缓解。然而,瓣周漏症状患者的死亡率仍然很高。长期临床疗效高度依赖于残余反流。